Outlook Therapeutics, Inc. - 8-K Filing
Outlook Therapeutics regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after its stock closed at or above that level for 10 consecutive business days from June 11, 2026 to June 25, 2026. As a result, the company will remain listed on the Nasdaq Capital Market and this delisting matter is now resolved. (Items: 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing)
Tickers: $OTLK